Alnylam Pharmaceuticals | La Marge Brute Sur Les Ventes



Gross Profit On Sales Changement Date
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amgen USD 5.97B 781M 2024-12
Arrowhead Research -173085000 2.55M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Moderna USD 420M 1.14B 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.24B 313M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Sanofi EUR 5.36B 4.71B 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Takeda JPY 727.25B 54.48B 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Xencor -45143000 40.69M 2024-09



Alnylam Pharmaceuticals La Marge Brute Sur Les Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.